RxDoctor Payments Data

Sarah McColley, PA

Physician Assistant · Grand Rapids, MINPI 1972533628

Payments from drug & device makers

$4,012in general payments, 2019–2025

Across 110 payments — averaging $36.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Johnson & Johnson$440
  • Sumitomo Pharma America, Inc.$351
  • Procept Biorobotics Corporation$214
  • Astellas Pharma US Inc$132
  • Boston Scientific$121
  • plus $1K from 29 others

What the payments were for

  • Travel & lodging$1,26932%
  • Food & beverage$2,57564%
  • Education$1684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,012 in reported general payments places this provider in the 90th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$19,167
Medicare patients
132
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron195$131,728
GemtesaVibegron36$34,907
Estradiol168$11,111
PremarinEstrogens, Conjugated16$6,556
Trospium Chloride31$2,963
Methenamine Hippurate20$2,216
Tamsulosin Hcl65$909
Solifenacin Succinate18$870
Cephalexin128$718
Potassium Citrate ErPotassium Citrate12$612
Finasteride16$206
Cefdinir18$156
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$150
Ciprofloxacin Hcl14$84
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$132$131,728195 claims
Sumitomo Pharma America, Inc.Gemtesa$351$34,90736 claims
PfizerPremarin$66$6,55616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →